NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
TOP NEWS
»23/08/2009 [Industry news]
ChinaBio Week

Industry news over the last week

 
By ChinaBio Today The FDA granted a permit to begin a Phase II trial of a TCM, Fuzheng Huayu capsules, in patients with hepatitis C who have developed fibrosis of the liver. The trial will be conducted by researchers at the University of California at San Diego. Fuzheng Huayu could become the first TCM to win approval from the FDA, if all goes well. Fuzheng Huayu was developed by the Shanghai University of Traditional Chinese Medicine. It has been used in China since 2002, where it is produced by the Shanghai Sundise Chinese Medicine Technology Development Co. Another TCM proved its efficacy against rheumatoid arthritis in a clinical study, as reported in the most recent edition of the journal Annals of Internal Medicine. The remedy, known popularly (and most colorfully) as thunder god vine or lei gong teng, is derived from the medicinal plant Tripterygium wilfordii Hook F [TwHF]. In a clinical study, TwHF was compared with a sulfa drug. TwHF was almost twice as effective at decreasing joint swelling and pain as the sulfa drug. For the first time, US Pharmacopeia has verified the quality of a traditional Chinese medicine product. The nonprofit, standards-setting organization has granted its (USP Verified) mark to ONCO-Z Coriolus Versicolor Extract, a mushroom-derived product that is produced by Hong Kong manufacturer PuraPharm International. The TCM is used in China to fight cancer. Outside the TCM world, China Pharma Holdings was given SFDA approval for Omeprazole Sodium injection, a proton pump inhibitor that is prescribed for gastroesophageal reflux disease (GERD) and other conditions caused by excessive stomach acid. The drug is a generic form of Losec and Prilosec, marketed by AstraZeneca. Although most Omeprazole products are oral, China Pharma’s formulation is an injection, which enters the blood circulation more quickly and avoids degradation in the stomach. On the medical device front, Avita Medical, an Australian medical device company, received SFDA approval for its ReCell Autologous Spray-On Skin, a one-use kit that harvests a patient’s skin cells and then reapplies them in a spray. ReCell kits are used for both to aid wound healing and for cosmetic purposes. Helicon Group, which oversaw the China approval process for Avita, will distribute ReCell through an established network of partners that specialize in medical devices. Sinovac Biotech reported that its swine flu (H1N1) vaccine was effective after a single dose. The seropositive rate, seroconvertive rate and GMT-increasing multiple reached the international criteria for vaccines. The top-line results were unblinded in Beijing this week, allowing Sinovac to claim bragging rights as the first vaccine manufacturer in the world to complete a successful test of a swine flu vaccine. China Sky One Medical reported record high results for Q2 of 2009, and the company reiterated its guidance for full-year 2009. During the second quarter, revenue climbed 36% to $32.2 million, while net income rose 17% to $9.5 million. China Sky One said it remains on track to achieve its 2009 goals of $128-130 million of revenue, a 40% increase, and net income of $38-39 million. Sinovac Biotech also announced good results for its Q2, thanks largely to a single $12.8 million order for its major product, the hepatitis A vaccine Healive®. Sinovac said Q2 revenues were up 21% at $20 million while net income increased a much larger 74% to $5.8 million. According to Sinovac, 89% of the $12.8 million order was filled during Q2. That means $11.4 million of the company’s $20 million in Q2 revenues derived from the one-time event. The company expects a similarly large set of orders for its swine flu vaccine to maintain the high momentum.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.